• Pear Therapeutics Announces FDA Submission for Somryst americanpharmaceuticalreview
    July 19, 2019
    Pear Therapeutics announced the filing of a submission to the U.S. Food and Drug Administration (FDA) seeking marketing authorization for Somryst™, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia
  • PEAR Therapeutics Scores $50M in Series B Funding Round biospace
    January 03, 2018
    Digital therapy pioneer Pear Therapeutics Temasek led the $ 5.9 million in Series B financing, joined the new and existing investors 5AM Ventures
PharmaSources Customer Service